SIOGEN Biotech, is the sole proprietary owner of Siosomes^® technology, a nanotechnology platform for the delivery of drugs, compounds and substances.

The “Siosomes^® Technology” can be used for all forms or mode of administration be it oral, transdermal, inhalation, gel, IV and IM as well.

It is also applicable for generics, cosmetics and herbal compounds as well. Through Siosomes^®, new IPs can be created thus providing life cycle extensions for existing drugs and LCM.

We offer a very attractive business model, whereby we will partner with our clients, and share our Siosomes^® technology for the development of drugs, vaccines and etc in exchange for upfront license fees, milestones, and royalties.

If you want a superior and effective solution to save your drug development programme contact us.